Introduction
Antigen-specific CD4 + T cells play an important role in allergic sensitization by secreting lymphokines that promote IgE synthesis and support the growth or maturation of effector cells such as eosinophils and mast cells (1) Protein antigens derived from the house dust mite (HDM), Dermatophagoides pteronyssinus are a common source of aeroallergens in the environment, -10% of the population develop allergies to HDM resulting in clinical symptoms including perennial rhinitis, atopic dermatitis or asthma (1) . At present desensitization therapy is not successful for most HDM allergic patients and more effective methods of modulating the allergic immune response are required. Recently it has been shown that human HDM-reactive CD4 + T cells can be inactivated in vitro by exposing them to supraoptimal concentrations of their cognate peptide (2,3) Furthermore, it is possible to inhibit the function of allergen-reactive T cells in vivo by either intranasal (i.n.) or oral administration of a peptide containing the immunodominant T cell epitope derived from the HDM allergen Der p 1 in H-2 13 mice (4, 5) . These results suggest that peptide-mediated immune regulation may be useful in allergen immunotherapy as has been demonstrated in the prevention of experimental autoimmune diseases (6) (7) (8) (9) .
Administration of antigens via mucosal surfaces is an effective way of inhibiting antigen-specific T cell responses in vivo. Oral tolerance to protein antigens results in the inhibition of antigen-specific CD4 + T cell responses in vitro by either clonal deletion, clonal anergy or active suppression depending on the dose of antigen administered (10, 11) . + 
T cells responses with peptide
Little is known about the mechanisms that regulate immune responses following high-dose antigen treatment through the respiratory tract. In rats continuously exposed to low doses of nebulized protein, CD4 + T cells become primed to the antigen and secrete IL-2 and IL-4 (12) The CD4 + T cell response, however, is then suppressed by the activation of IFN-y-secreting CD8 + T cells and these suppressor cells abrogate the induction of IgE synthesis in naive recipients upon adoptive transfer (12) (13) (14) . In this paper we have begun to elucidate the cellular mechanisms which give rise to the development of antigen-specific T cell tolerance following i.n. administration of peptide. We examined the nature of the primary T cell response elicited by high doses of i.n. peptide and investigated the role of CD8 + T cells in the induction of tolerance We also demonstrate that rechallenging mice with i.n. peptide after 3 weeks after the initial treatment elicits a further transient T cell response to the peptide. These studies have important implications in understanding the response to mucosally delivered peptides in immunotherapy.
Methods

Animals
Inbred female C57BL/6J mice were purchased from Harlan OLAC (Bicester, UK) at 6-8 weeks of age and were kept in isolators. CD8"'" mice were obtained as a fifth generation backcross on the C57BL/6J background and bred under conventional conditions. The mice were kindly provided by Dr Dimitri Kioussis (National Institute of Medical Research, The Ridgeway, Mill Hill, UK).
Antigens
The synthetic peptide p1 111-139 was derived from the Der p 1 sequence and was synthesized using standard f-moc chemistry
Antibodies
Monoclonal antibodies specific for murine CD4 (YTS.191.2.1) and CD8 (Lyt2,53.5.) were obtained from the European Tissue Culture Collections. The murine anti-l-A b mAb (M5/114) was a kind gift from Dr R. Lechler. Cervical lymph node (LN) cells from peptide-treated mice were cultured with mAb supernatants or a control rat anti-mouse IgG at 1/20 and 1/ 100 dilution in the presence or absence of peptide for 24 h at 37°C. Supernatants were collected and assayed for the presence of lymphokines
Induction of Tcell non-responsiveness by inhalation of peptide
Mice were lightly anaesthetized with ether and the peptide p1 111-139 (100 ng) dissolved in 20 nl of PBS was administered i.n. using a micropipette on three consecutive days. Mice were immunized s.c. at the base of the tail 14 days after the last treatment with 50 \ig of Der p 1 emulsified in complete Freund's adjuvant (CFA), (Difco, Detroit, Ml) in a volume of 0.2 ml.
Culture medium
LN or spleen cells were cultured in RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 2% FCS (Gibco), 50 nM 2-mercaptoethanol (Sigma, St Louis, MO), 2 mM L-glutamine (Sigma) and 20 ng/ml penicillin/streptomycin. CTLL-2 cells were maintained in RPMI 1640 (Gibco) and 10% FCS, while FDC-P1 cells were cultured in DMEM plus 5% FCS.
T cell assays
The cervical LNs were pressed through a stainless steel wire mesh, washed and cultured at 4X10 5 cells in 0.2 ml culture medium in 96-well flat-bottom tissue culture plates (Becton Dickinson Labware, Lincoln Park, NJ) at 37°C. Protein or peptide antigen was added at various concentrations and supernatants were collected at 24 or 48 h and stored at -20°C until assayed
Lymphokine assays
The CTLL-2 cell line proliferates maximally with IL-2 but only poorly in the presence of IL-4 (15 IFN-ywas measured using an ELISA assay. Briefly, rat antimouse IFN-y mAb (R4-6A2; PharMmgen) was coated onto lmmulon-2 plates overnight and washed with PBS containing 0.05% Tween 20 (Sigma). Plates were blocked with 10% BSA dissolved in PBS After washing, culture supernatants were added to the plates and incubated for 2 h at room temperature Plates were washed and the presence of bound IFN-y detected by biotinylated anti-mouse IFN-y (XMG1.2, PharMingen). Plates were developed using streptavidin-alkaline phosphatase (Sigma) with 3,3'-5,5'-tetramethyl benzidine (Sigma) as the substrate. Plates were read at 405 nm.
Antibody measurements
The p1 111-139 peptide was coated onto lmmulon-4 microtitre plates at 10 |ig/ml overnight at 4°C. Plates were blocked with PBS containing 10% BSA. After washing, serum dilutions were added to the plate and incubated for 2 h at room temperature. Plates were washed and the presence of bound antibody was detected isotype-specific biotinylated antibodies (Southern Biotechnology Associates). Plates were washed and developed using streptavidin-alkaline peroxidase (Sigma) with 3,3'-5,5'-tetramethyl benzidine (Sigma) as the substrate. Results expressed as OD absorbance units at 405 nm.
Regulation of CD4 + T cells responses with peptide 337
Results
T cells undergo transient activation during the induction phase of non-responsiveness
In order to investigate the effect of i.n. peptide on the effector function of antigen-specific T cells in vivo, C57BL/6J mice were treated i.n. on three consecutive days with 100 |ig of p1 111-139. This regime has previously been shown to be effective in inducing peripheral tolerance to Der p 1 in naive mice. The response of T cells in the draining cervical LN and spleen of i.n. treated mice was examined at various times over a 28 day period and their capacity to secrete lymphokines following antigenic challenge in vitro was determined. When T cells are re-stimulated with peptide in vitro on day 2 they secrete high levels of IL-3/GM-CSF but only low levels of IFNyand IL-2 ( Fig. 1) . By day 4, p1 111-139-specific T cells in the LN and spleen display their highest level of secretion of IL-2, IL-3/GM-CSF and IFN-y (Fig 1) with little or no IL-4 (not shown). By day 8 T cell responses in the cervical LN and spleen had begun to decline, and on day 14 and day 28 peptide-specific T cells secreted only low levels of IL-3/GM-CSF and no IL-2 or IFN-y when stimulated in vitro ( Fig. 1 ). During the first 4 days after peptide inhalation there was a rapid increase in the cellularity of the cervical LN that declined over time (Fig. 1d) . Spleen cell numbers, however, did not change significantly over the same period. Thus it would appear that by day 14 antigen-specific T cells were anergic as defined by their inability to secrete IL-2 when stimulated in vitro.
Identification of the phenotype of the cell responding to peptide
It was important to identify the phenotype of the T cells which responded to the i.n. peptide. Mice were treated i.n. with 100 u.g of p1 111-139 on three consecutive days and 4 days later the cervical LN were cultured with 10 |ig/ml p1 111-139 either in the presence or absence of mAbs against CD4, CD8, class II MHC or a control antibody (rat anti-IgG) Cells treated with the control antibody responded strongly to the peptide in vitro secreting IL-2, IL-3/GM-CSF (Fig. 2) and IFN-y (not shown).
Treating cells with a 1/20 dilution of anti-CD4 mAb inhibited lymphokine secretion in response to the peptide, while anti-CD8 antibody had no effect ( to high-dose HDM peptide are class II MHC restricted and express CD4 co-receptor.
Comparison of antigen-specific T cell responses following an activating or tolerizing challenge with antigen
Mice were treated i.n. with 3x100 \ig of p1 111-139 or were immunized at the scruff of the neck with 50 ng Der p 1/CFA.
T cell responses were measured in the cervical LN on days 4, 8 and 14 after both forms of challenge, and production of IL-2 and IFN-y was examined. On day 4 there was little difference in the T cell responses of mice receiving the tolerizing or activating challenges with antigen. T cells from both groups secreted equivalent levels of IL-2 and IFN-y (Fig. 3) . However, by day 8 T cells from the peptide-treated mice had begun to down-regulate their cytokine secretion, and this was most noticeable by day 14 (Fig. 3) .
CD8* T cells do not play a role in the maintenance of peripheral tolerance to inhaled peptide
To examine whether regulatory CD8 + T cells play a role in inhibiting the function of antigen-specific CD4 + T cells following i.n. peptide treatment we used mice deficient in CD8 + T cells. The CDS"'" mice were treated with PBS or with p1 111-139 i.n. using the standard tolerance protocol. Following Der p 1 immunization, LN cells from PBS treated animals were still responsive and could secrete IL-2 when stimulated in vitro with either Der p 1 or the dominant peptide (Fig. 4) . CDS"'" mice that had been pretreated with p1 111-139 i.n. had downregulated antigen-specific T cell responses to both the protein and the peptide, typical of wild-type mice (Fig. 4) .
Intranasal peptide challenge in vivo after anergy induction results in further transient antigen-specific IL-2 production
Twenty-one days after i.n. peptide, antigen-specific T cells in the regional LN and spleen fail to secrete IL-2 when stimulated in vitro with p1 111-139. Thus we wished to examine if peptide-specific T cells would remain anergic after a further i.n. challenge with p1 111-139. Four days after the in vivo rechaJlenge, T cells from the cervical LN and spleen secreted IL-2 and IL-3/GM-CSF in an antigen-specific manner when stimulated in vitro with peptide (Fig 5) . In comparison, T cells from unchallenged mice failed to secrete IL-2 and only low + T cells responses with peptide levels of IL-3/GM-CSF (Fig. 5) . However, the secretion of IL-2 by peptide-specific T cells was only transient, and by day 14, T cells had again down-regulated IL-2 production. It should be noted that despite the transient release of IL-2 from T cells upon rechallenge with peptide in vivo mice remained unresponsive to a challenge with Der p 1/CFA.
We were interested in determining if the same effect would be seen after parenteral challenge with Der p IL-2 at high levels on both days 4 and 10 post-challenge (Fig. 6) , whereas on the other hand T cells from peptidetreated mice failed to secrete IL-2 at either time point (Fig. 6) .
Peptide inhalation does not elicit a significant antibody response
Since inhalation of peptide induced a vigorous T cell response we wanted to determine if there were any serum antibodies produced to the peptide. Mice were treated with 3x100 ng p1 111-139 i.n. and bled on day 14 after the last treatment (Group 1, Fig 7) . The level of peptide-specific antibodies in the serum was low and predominantly of the IgM isotype with a small amount of lgG2a (Fig. 7) . Unlike the T cell response we did not observe any significant rise either in the level of peptide-specific antibodies or a switch to the IgG isotype in mice who were rechallenged twice with p1 111-139 i.n. at fortnightly intervals (Group 2, Fig 7) .
Discussion
We report here that i.n. administration of a high dose of HDMderived peptide elicits a strong but transient activation of The failure of T cells to secrete IL-2 following antigenic stimulation has been used as a definition for clonal anergy (16) However, from our studies it would appear that the development of anergy in vivo occurring as a consequence of i.n. peptide is mediated by a different mechanism to that proposed for anergy in vitro (17, 18) . After peptide i.n. CD4 + T cells still secrete IL-2 , and therefore, must have received costimulation from antigen-presenting cells (APCs). Nevertheless, the signals which mucosal APCs deliver to the naive T cells must in some way prime these cells to become nonresponsive (anergic). Studies to date have suggested that mucosal APCs do not have an intrinsic tolerogenic capacity (19) . Whether or not certain populations of APCs are able to deliver inhibitory signals that override the known positive costimulatory signals such as those mediated by the B7 family of molecules is not known.
Our findings are consistent with previous studies which have also demonstrated that CD4 + or CD8 + T cells responding to various tolerogens undergo a state of transient activation prior to the development of non-responsiveness (20-24) However, we have obtained no direct evidence for a shift in cytokine production by CD4 + T cells over time following the induction of tolerance to i.n. peptide. This is in contrast to recent findings which show that the development of peripheral CD4 + T cell tolerance following immunization of mice with ovalbumin in incomplete Freund's adjuvant (25) . Others suggest a role of CD8 + T s cells in the regulation of IgE responses in mice and rats exposed to nebulized antigen (13, 14, 26) . However, we failed to demonstrate that CD8 + T cells regulate either the induction or maintenance of tolerance to peptide administered i.n., similar to that described for the induction of oral tolerance (27) . There is a possibility that CD8 + T 8 cells may function when low doses of antigen are encountered by the immune system, such as in the maintenance of oral tolerance induced by feeding low doses of protein antigen (10) . It should be noted that we have only examined responses to high doses of peptide given i.n., which may occur via distinct mechanisms.
Two weeks after peptide treatment, T cells in the draining cervical LN failed to secrete IL-2 when challenged in vitro. However, if mice were challenged 21 days after their initial treatment with a single 100 ng dose of peptide i.n., then within 4 days of the challenge, antigen-specific T cells capable of secreting IL-2 were detected in the cervical LN and spleen. The capacity of these T cells to secrete IL-2 was only transient and was down-regulated by 2 weeks. It would appear that IL-2 production on peptide rechallenge in vivo did not abrogate peripheral tolerance to the HDM protein, since these same animals were still unresponsive to a parenteral challenge with Der p 1/CFA if given 14 days after the i.n. rechallenge. Furthermore, if mice are continuously rechallenged with peptide i.n. once every 2 weeks then by day 4 after the last rechallenge the presence of IL-2 secreting cells in the cervical LN and spleen is observed. Similar responses have also been shown to occur with periodic feeding of high doses of antigen to mice (28) and with tolerance to the superantigen staphylococcal enterotoxin B (SEB) (29 + T cell response that occurs to the i n. peptide these cells fail to provide effector help to B cells to induce Ig class switching. Although some IgM peptidespecific antibodies are present, no IgG antibodies can be detected in the serum of mice. Our findings suggest that the transient IL-2 response observed after peptide rechallenge is from naive T cells that have not yet been tolerized to the peptide. What is clear from these experiments is that the development of peripheral tolerance to i.n. administered, or fed, antigens is not complete after the first encounter with antigen, but instead the immune system continuously responds to these antigens in a negative way that acts to preserve tolerance It is possible that the development of mucosal tolerance involves more than one mechanism in order to control responses to common dietary or inhaled antigens. For example, following high-dose antigen treatment some T cells may undergo apoptosis as a result of antigen recognition (11, 30) , a subset of cells may escape death but become anergic (31) In addition, negative responses mediated by regulatory T s cells may be superimposed on these effects (14, 26) . Therefore, different overlapping mechanisms of immune regulation at mucosal surfaces may provide for an efficient control over immune responses to normal environmental antigens.
Our results have important implications for the use of peptides in immunotherapy. Currently a clinical trial is in progress investigating the efficacy of synthetic peptides derived from the Fel day 1 allergen to ameliorate allergic symptoms in cat allergic individuals (32) . Our results are likely to provide an insight into the mechanisms of how mucosally delivered peptides induce peripheral tolerance in CD4 + T cells in vivo. In addition we have demonstrated that the immune system continuously responds to the peptide tolerogen on periodic challenge in vivo. This is an important observation since patients undergoing peptide immunotherapy are expected to receive peptide injections every 3-4 weeks over an extended period of time. Clearly information is required to better understand the cellular and molecular basis for tolerance induction by peptides delivered through mucosal surfaces. This will require examination of the nature of mucosal APCs and the nature of the signals delivered to the T cells. + T cells responses with peptide GM-CSF granulocyte macrophage colony stimulating factor HDM house dust mite i.n. intranasal LN lymph node SEB staphylococcal enterotoxin B
